Please assess the completion status of the following clinical trial:

Trial Title: A Safety and Dose Finding Trial of C-Tb, When Given to Adult Patients Recently Diagnosed With Active Tuberculosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~The patient:~1. Has signed an informed consent~2. Is willing and likely to comply with the trial procedures~3. Has been diagnosed with active TB and has been in treatment ≤ 60 days at the time of inclusion~   * has 1 documented positive sputum smear microscopy result~  * has positive culture~  * has a positive PCR result for tuberculosis~  * has a compatible clinical picture of TB with the intention to treat~4. Has a positive T-spot assay or a QuantiFERON®-TB Gold In Tube test~5. Is prepared to grant authorized persons access to their medical records~Exclusion Criteria:~The patient:~1. Has been in treatment with a product which is likely to modify the immune response within 3 months prior to the day of inclusion (e.g., immunoglobulin, systemic corticosteroids, methotrexate, azathioprine, cyclosporine or blood products)~2. Has been vaccinated with a live vaccine within 6 weeks prior to the day of inclusion (e.g. BCG, MMR, yellow fever, oral typhoid vaccines)~3. Has a known congenital or acquired immune deficiency~4. Has a disease affecting the lymphoid organs (e.g., Hodgkin's disease, lymphoma, leukaemia, sarcoidosis)~5. Is infected with HIV~6. Has severe scarring, burn, rash, eczema, psoriasis, or any other skin disease at or near the injection sites~7. Has a condition where blood drawings pose more than minimal risk for the patient, such as haemophilia, other coagulation disorders, or significantly impaired venous access~8. Is actively participating in another clinical trial~9. Is pregnant according to urine pregnancy test at inclusion~10. Has a condition which in the opinion of the investigator is not suitable for participation in the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- 0.01µg C-Tb (Type: EXPERIMENTAL): 12-24 patients depending on a safety evaluation will receive a low dose of 0.01 µg/0.1 mL C-Tb without phenol in the RIGHT or LEFT arm and 0.01 µg/0.1 mL C-Tb with phenol in the opposite arm, in a double blind manner.
- 0.1µg C.Tb (Type: EXPERIMENTAL): 12-24 patients depending on a safety evaluation will receive a high dose of 0.1 µg/0.1 mL C-Tb without phenol in the RIGHT or LEFT arm and 0.01 µg/0.1 mL C-Tb with phenol in the opposite arm, in a double blind manner.

Based on this trial design, predict the completion outcome and termination type (if applicable).